|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,484.50 JPY | +0.81% |
|
+7.90% | +14.36% |
| Capitalization | 1,167B 7.44B 6.29B 5.77B 5.46B 10.15B 674B 10.61B 67.04B 26.54B 324B 27.89B 27.31B | P/E ratio 2026 * |
17x | P/E ratio 2027 * | 16.1x |
|---|---|---|---|---|---|
| Enterprise value | 1,097B 6.99B 5.91B 5.42B 5.13B 9.53B 633B 9.97B 62.99B 24.94B 305B 26.2B 25.66B | EV / Sales 2026 * |
2.19x | EV / Sales 2027 * | 2.11x |
| Free-Float |
79.73% | Yield 2026 * |
3.14% | Yield 2027 * | 3.14% |
Last Transcript: Ono Pharmaceutical Co., Ltd.
| 1 day | +0.81% | ||
| 1 week | +7.90% | ||
| Current month | +7.90% | ||
| 1 month | +12.29% | ||
| 3 months | +28.83% | ||
| 6 months | +45.98% | ||
| Current year | +14.36% |
| 1 week | 2,293 |  | 2,492 |
| 1 month | 2,202 | | 2,492 |
| Current year | 2,147.5 | | 2,492 |
| 1 year | 1,474 | | 2,492 |
| 3 years | 1,474 | | 2,966.5 |
| 5 years | 1,474 | | 3,990 |
| 10 years | 1,474 | | 5,880 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gyo Sagara
CEO | Chief Executive Officer | 67 | 2024-03-31 |
Toichi Takino
PSD | President | 57 | 2024-03-31 |
Shinji Takai
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Gyo Sagara
CHM | Chairman | 67 | 2024-03-31 |
Toichi Takino
BRD | Director/Board Member | 57 | 2020-05-31 |
Masao Nomura
BRD | Director/Board Member | 76 | 2018-06-25 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +5.19% | 3.23% | 29 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.81% | +7.90% | +61.65% | -12.13% | 7.44B | |
| -0.44% | +6.26% | -3.13% | +68.43% | 44.89B | |
| -1.46% | +1.11% | +17.89% | +128.57% | 31.43B | |
| -0.25% | +0.45% | -9.66% | +28.96% | 11.86B | |
| -1.86% | +0.32% | -10.66% | +85.24% | 9.86B | |
| -0.86% | +0.43% | +40.43% | +124.27% | 8.31B | |
| +0.70% | +4.06% | +148.76% | +839.85% | 7.95B | |
| -0.80% | +0.87% | +58.79% | +26.49% | 7.6B | |
| -.--% | +0.14% | - | - | 6.79B | |
| +1.32% | +6.59% | +9.86% | +42.79% | 6.55B | |
| Average | -0.28% | +3.51% | +34.88% | +148.05% | 14.27B | |
| Weighted average by Cap. | -0.56% | +3.67% | +19.80% | +120.66% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 500B 3.19B 2.7B 2.47B 2.34B 4.35B 289B 4.54B 28.72B 11.37B 139B 11.95B 11.7B | 497B 3.16B 2.68B 2.46B 2.33B 4.32B 287B 4.51B 28.53B 11.3B 138B 11.87B 11.63B |
| Net income | 68.99B 439M 372M 341M 323M 600M 39.81B 627M 3.96B 1.57B 19.17B 1.65B 1.61B | 72.54B 462M 391M 358M 339M 630M 41.86B 659M 4.17B 1.65B 20.15B 1.73B 1.7B |
| Net Debt | -70.67B -450M -381M -349M -331M -614M -40.78B -642M -4.06B -1.61B -19.63B -1.69B -1.65B | -119B -760M -643M -589M -558M -1.04B -68.82B -1.08B -6.85B -2.71B -33.13B -2.85B -2.79B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-02-06 | 2,484.50 ¥ | +0.81% | 1,887,700 |
| 26-02-05 | 2,464.50 ¥ | +1.25% | 2,213,100 |
| 26-02-04 | 2,434.00 ¥ | +0.93% | 2,208,400 |
| 26-02-03 | 2,411.50 ¥ | +1.26% | 3,260,500 |
| 26-02-02 | 2,381.50 ¥ | +3.43% | 3,476,000 |
Delayed Quote Japan Exchange, February 06, 2026 at 01:30 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 4528 Stock
Select your edition
All financial news and data tailored to specific country editions
